Actively Recruiting
Pharmacogenomics of Stimulant Treatment Response
Led by University of Calgary · Updated on 2025-12-05
400
Participants Needed
1
Research Sites
247 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The "Pharmacogenomics of Stimulant Treatment Response" (PGx-STaR) study aims to identify genetic profiles related to methylphenidate treatment outcomes in children and adolescents aged 6-24 with Attention deficit/hyperactivity disorder (ADHD).
CONDITIONS
Official Title
Pharmacogenomics of Stimulant Treatment Response
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Aged 6 to 24 years
- Living in Western Canada (Alberta, British Columbia, Saskatchewan, Manitoba)
- Primary diagnosis of ADHD (all types)
- Starting treatment with slow-release methylphenidate (not immediate release)
You will not qualify if you...
- Having psychotic, bipolar, or eating disorders
- Significant risk of suicide
- Intellectual disability, autism spectrum disorder, or tics/Tourette disorders
- High-risk alcohol or substance use monthly or more in the past 12 months
- Starting or changing psychotherapy or brain stimulation therapy within 8 weeks of referral
- History of liver or bone marrow transplant
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Calgary
Calgary, Alberta, Canada
Actively Recruiting
Research Team
W
Weng-Sam Siu, MSPT, MSc
CONTACT
M
Madison Heintz, MSW
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here